Valproate (Epilepsy)

Low Apgar score (< 7) (at 1 min)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5931
R15126
Artama (Valproate) (Controls exposed to Lamotrigine, sick), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.31 [0.62;2.73] C
excluded (control group)
45/600   9/154 54 600
ref
S5911
R14905
Artama (Valproate) (Controls unexposed, disease free), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.76 [1.29;2.39]
excluded (control group)
45/600   27,939/689,482 27,984 600
ref
S5919
R15001
Artama (Valproate) (Controls unexposed, sick), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective unexposed, sick Adjustment: Yes 1.78 [1.20;2.66] 45/600   69/1,708 114 600
ref
S6416
R17616
Pennell (Valproate), 2012 Apgar score (at 1 minute < 7) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 6.78 [2.12;21.73] C 14/62   4/97 18 62
ref
S8221
R25744
Endo (Valproate) (Controls unexposed, disease free), 2004 Apgar score (<8 at 1min) at least 1st trimester retrospective cohort unexposed, disease free excluded Adjustment: No 0.54 [0.03;10.27] C
excluded (control group)
0/5   47/280 47 5
ref
S8311
R26301
Endo (Valproate) (Controls unexposed, sick), 2004 Apgar score (<8 at 1min) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 0.11 [0.00;14.76] C 0/5   0/1 0 5
ref
Total 3 studies 2.54 [0.71;9.05] 132 667
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Artama (Valproate) (Controls unexposed, sick), 2013Artama, 2013 1 1.78[1.20; 2.66]11460055%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Pennell (Valproate), 2012Pennell, 2012 2 6.78[2.12; 21.73]186239%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Endo (Valproate) (Controls unexposed, sick), 2004Endo, 2004 3 0.11[0.00; 14.76]056%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 66% 2.54[0.71; 9.05]1326670.020.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate) (Controls unexposed, sick; 2: Valproate; 3: Valproate) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.54[0.71; 9.05]13266766%NAArtama (Valproate) (Controls unexposed, sick), 2013 Pennell (Valproate), 2012 Endo (Valproate) (Controls unexposed, sick), 2004 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.36[0.27; 6.84]11460519%NAArtama (Valproate) (Controls unexposed, sick), 2013 Endo (Valproate) (Controls unexposed, sick), 2004 2 exposed to other treatment, sickexposed to other treatment, sick 6.78[2.12; 21.73]1862 -NAPennell (Valproate), 2012 1 Tags Adjustment   - No  - No 1.77[0.04; 77.53]186761%NAPennell (Valproate), 2012 Endo (Valproate) (Controls unexposed, sick), 2004 2   - Yes  - Yes 1.78[1.20; 2.65]114600 -NAArtama (Valproate) (Controls unexposed, sick), 2013 1 All studiesAll studies 2.54[0.71; 9.05]13266766%NAArtama (Valproate) (Controls unexposed, sick), 2013 Pennell (Valproate), 2012 Endo (Valproate) (Controls unexposed, sick), 2004 30.020.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8221, 5931, 5911

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.76[1.29; 2.40]27,984600 -NAArtama (Valproate) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 1.36[0.27; 6.84]11460519%NAArtama (Valproate) (Controls unexposed, sick), 2013 Endo (Valproate) (Controls unexposed, sick), 2004 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.79[0.56; 13.95]7266282%NAArtama (Valproate) (Controls exposed to Lamotrigine, sick), 2013 Pennell (Valproate), 2012 20.510.01.0